Asset Details
Do you wish to reserve the book?
Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation
Do you wish to request the book?
Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation
2026
Overview
IntroductionAcute lung injury (ALI) and acute respiratory distress syndrome (ARDS) represent a spectrum of acute respiratory failure arising from the same underlying pathophysiological processes and are associated with substantial morbidity and mortality worldwide. Although corticosteroids such as Dexamethasone are commonly administered to patients with moderate-to-severe ARDS, their clinical benefit remains controversial, and systemic administration is often associated with significant adverse effects.MethodsWe developed a targeting ligand-free, sulfonium lipid nanoparticle (sLNP)-based drug delivery system, Dex/DOSEH, for intravenous lung-targeted delivery of dexamethasone.ResultsIn a lipopolysaccharide (LPS)-induced murine ALI model, treatment with Dex/DOSEH formulation significantly reduced proinflammatory cytokine production, decreased immune cell infiltration, preserved capillary-alveolar barrier integrity, and attenuated histopathological lung injury compared with controls.DiscussionOur findings demonstrate that Dex/DOSEH drug formulation enables effective lung-targeted delivery of dexamethasone and achieves robust anti-inflammatory therapeutic efficacy in ALI. This platform represents a promising therapeutic strategy for the treatment of ALI/ARDS.
Publisher
Frontiers Media S.A
Subject
